What is Mazdutide?
Mazdutide (formerly known as IBI362) is an experimental GLP-1 and glucagon receptor agonist for weight loss and type 2 diabetes treatment.
Like tirzepatide (Mounjaro) and retatrutide, mazdutide is part of the new generation of multi-receptor weight-loss drugs.
How Does Mazdutide Work?
Mazdutide activates two key receptors:
- GLP-1 (Glucagon-like peptide-1) receptor – Reduces appetite, slows digestion, and helps with blood sugar control.
- Glucagon receptor – Increases energy expenditure and fat burning.
It does not activate the GIP receptor, unlike tirzepatide and retatrutide.
Effectiveness in Clinical Trials
- In Phase 2 trials, patients on 9 mg mazdutide lost an average of 15.4% of their body weight over 48 weeks.
- Blood sugar levels and cholesterol also improved significantly.
- The weight loss effect is similar to semaglutide (Wegovy, Ozempic) but less than tirzepatide (Mounjaro) or retatrutide.
Reviews
There are no reviews yet.